MDGL$396.328.08%-34.83
After Hours: 396.00-0.32 -0.08%
Madrigal Pharmaceuticals Inc (MDGL)
Date: 2026-11-03 16:00O: 449.32H: 482.73L: 387.33C: 396.32Vol: 1.981M
Madrigal Pharmaceuticals Inc stock is traded at $396.32, with a volume of 1,980,937. It is down -8.08% in the last 24 hours and down -20.64% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Previous Close:
$431.16
Open:
$449.32
24h Volume:
1,980,937
Relative Volume:
4.34
Market Cap:
$9.16B
Revenue:
$1.13B
Net Income/Loss:
-$309.44M
P/E Ratio:
-
EPS:
-$12.80
Net Cash Flow:
-$275.41M
1W Performance:
-9.99%
1M Performance:
-20.64%
6M Performance:
-22.85%
1Y Performance:
-3.89%
1-Day Range:
$387.33$482.73
1-Week Range:
$387.33$482.73
52-Week Range:
$387.33$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
404-380-9263Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Madrigal Pharmaceuticals Inc Stock (MDGL) Insider Trading
- PAUL FRIEDMANSep 28 '26Director
- Transaction
- Proposed Sale
- Cost
- $516.56
- #Shares
- 50,000
- Value ($)
- 25,828,000
- #Shares Total
- 0
- WILLIAM SIBOLDSep 11 '26Director
- Transaction
- Proposed Sale
- Cost
- $533.12
- #Shares
- 5,221
- Value ($)
- 2,783,420
- #Shares Total
- 0
- Sibold William JohnSep 11 '26President and CEO
- Transaction
- Sale
- Cost
- $542.39
- #Shares
- 5,221
- Value ($)
- 2,831,801
- #Shares Total
- 197,746
- William John SiboldSep 09 '26Officer and Director
- Transaction
- Proposed Sale
- Cost
- $534.16
- #Shares
- 6,362
- Value ($)
- 3,398,326
- #Shares Total
- 0
- Sibold William JohnSep 09 '26President and CEO
- Transaction
- Sale
- Cost
- $535.59
- #Shares
- 6,362
- Value ($)
- 3,407,397
- #Shares Total
- 202,967
- Shannon KelleyAug 17 '26Officer
- Transaction
- Proposed Sale
- Cost
- $507.56
- #Shares
- 664
- Value ($)
- 337,020
- #Shares Total
- 0
- Kelley Shannon TAug 17 '26General Counsel
- Transaction
- Sale
- Cost
- $514.97
- #Shares
- 664
- Value ($)
- 341,940
- #Shares Total
- 11,474
- William SiboldJul 20 '26Officer and Director
- Transaction
- Proposed Sale
- Cost
- $553.48
- #Shares
- 2,500
- Value ($)
- 1,383,700
- #Shares Total
- 0
- Sibold William JohnJul 20 '26President and CEO
- Transaction
- Sale
- Cost
- $547.30
- #Shares
- 2,500
- Value ($)
- 1,368,253
- #Shares Total
- 209,329
- DAVID SOERGELJun 01 '26Officer
- Transaction
- Proposed Sale
- Cost
- $497.27
- #Shares
- 1,042
- Value ($)
- 518,155
- #Shares Total
- 0
